In this proposal we provide a rationale for continued infrastructure support for the Singapore Chinese Health
Study that enrolled 63,257 Chinese men and women at baseline in the early 1990s in Singapore.
Infrastructure support is needed to maintain and enhance the established infrastructure for this unique cancer
epidemiology cohort with repeated collections of questionnaire survey data and biological samples from cohort
participants. To date, approximately 20% of the cohort participants were diagnosed with cancers; more than
5,500 cancer patients provided baseline biological samples collected before cancer diagnosis. In the next 5
years the Singapore Chinese Health Study will accrue an additional 4,000 new cancer cases, 2,000 of them
with available baseline biospecimens that will provide unique resources for development of biomarker-based
cancer epidemiological studies. With the completion of the genome-wide genotyping on the entire cohort and
exosome gene sequence in the next two years, this cancer epidemiology cohort will also provide unique
opportunity for examining the gene-environmental interaction on risk of cancer. Some of the novel findings
from this Asian population has provided a strong rationale for us to conduct chemoprevention trials in U.S.
populations. Leveraging the unique and advanced system of electronic medical records and disease registries,
we have virtually full retention of the participants; only less than 0.1% of the original cohort participants were
known to be lost to our monitoring and tracking cancer incidence, cancer mortality, and many other chronic
diseases due to their migration out of Singapore. During the next 5-year study period, we propose to: (1)
continue to follow up for all surviving participants for cancer incidence, cancer mortality, cause-specific death,
and other non-cancer health outcomes; (2) maintain and update the biorepositories; (3) update and integrate
all data elements from follow-up interviews, assessment of disease outcomes, dynamic biorepository
inventories, and new laboratory measurements into the master cohort database for research projects; and (4)
support and enhance innovative cancer epidemiological studies as cohort-specific ancillary projects and large
cohort consortium projects. We anticipate that the established resources of this Asian cohort will become even
more scientifically valuable over the next five years as the young participants, especially those who provided
baseline biological samples, will enter into the age of maximal cancer incidence, thereby increasing the
number of cancer cases that provide resources for pre-disease biomarker-based research projects.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.